Cargando…

Modifying Orthobiological PRP Therapies Are Imperative for the Advancement of Treatment Outcomes in Musculoskeletal Pathologies

Autologous biological cellular preparations have materialized as a growing area of medical advancement in interventional (orthopedic) practices and surgical interventions to provide an optimal tissue healing environment, particularly in tissues where standard healing is disrupted and repair and ulti...

Descripción completa

Detalles Bibliográficos
Autores principales: Everts, Peter A., Mazzola, Timothy, Mautner, Kenneth, Randelli, Pietro S., Podesta, Luga
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9687216/
https://www.ncbi.nlm.nih.gov/pubmed/36428501
http://dx.doi.org/10.3390/biomedicines10112933
_version_ 1784835949133299712
author Everts, Peter A.
Mazzola, Timothy
Mautner, Kenneth
Randelli, Pietro S.
Podesta, Luga
author_facet Everts, Peter A.
Mazzola, Timothy
Mautner, Kenneth
Randelli, Pietro S.
Podesta, Luga
author_sort Everts, Peter A.
collection PubMed
description Autologous biological cellular preparations have materialized as a growing area of medical advancement in interventional (orthopedic) practices and surgical interventions to provide an optimal tissue healing environment, particularly in tissues where standard healing is disrupted and repair and ultimately restoration of function is at risk. These cellular therapies are often referred to as orthobiologics and are derived from patient’s own tissues to prepare point of care platelet-rich plasma (PRP), bone marrow concentrate (BMC), and adipose tissue concentrate (ATC). Orthobiological preparations are biological materials comprised of a wide variety of cell populations, cytokines, growth factors, molecules, and signaling cells. They can modulate and influence many other resident cells after they have been administered in specific diseased microenvironments. Jointly, the various orthobiological cell preparations are proficient to counteract persistent inflammation, respond to catabolic reactions, and reinstate tissue homeostasis. Ultimately, precisely delivered orthobiologics with a proper dose and bioformulation will contribute to tissue repair. Progress has been made in understanding orthobiological technologies where the safety and relatively easy manipulation of orthobiological treatment tools has been demonstrated in clinical applications. Although more positive than negative patient outcome results have been registered in the literature, definitive and accepted standards to prepare specific cellular orthobiologics are still lacking. To promote significant and consistent clinical outcomes, we will present a review of methods for implementing dosing strategies, using bioformulations tailored to the pathoanatomic process of the tissue, and adopting variable preparation and injection volume policies. By optimizing the dose and specificity of orthobiologics, local cellular synergistic behavior will increase, potentially leading to better pain killing effects, effective immunomodulation, control of inflammation, and (neo) angiogenesis, ultimately contributing to functionally restored body movement patterns.
format Online
Article
Text
id pubmed-9687216
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96872162022-11-25 Modifying Orthobiological PRP Therapies Are Imperative for the Advancement of Treatment Outcomes in Musculoskeletal Pathologies Everts, Peter A. Mazzola, Timothy Mautner, Kenneth Randelli, Pietro S. Podesta, Luga Biomedicines Review Autologous biological cellular preparations have materialized as a growing area of medical advancement in interventional (orthopedic) practices and surgical interventions to provide an optimal tissue healing environment, particularly in tissues where standard healing is disrupted and repair and ultimately restoration of function is at risk. These cellular therapies are often referred to as orthobiologics and are derived from patient’s own tissues to prepare point of care platelet-rich plasma (PRP), bone marrow concentrate (BMC), and adipose tissue concentrate (ATC). Orthobiological preparations are biological materials comprised of a wide variety of cell populations, cytokines, growth factors, molecules, and signaling cells. They can modulate and influence many other resident cells after they have been administered in specific diseased microenvironments. Jointly, the various orthobiological cell preparations are proficient to counteract persistent inflammation, respond to catabolic reactions, and reinstate tissue homeostasis. Ultimately, precisely delivered orthobiologics with a proper dose and bioformulation will contribute to tissue repair. Progress has been made in understanding orthobiological technologies where the safety and relatively easy manipulation of orthobiological treatment tools has been demonstrated in clinical applications. Although more positive than negative patient outcome results have been registered in the literature, definitive and accepted standards to prepare specific cellular orthobiologics are still lacking. To promote significant and consistent clinical outcomes, we will present a review of methods for implementing dosing strategies, using bioformulations tailored to the pathoanatomic process of the tissue, and adopting variable preparation and injection volume policies. By optimizing the dose and specificity of orthobiologics, local cellular synergistic behavior will increase, potentially leading to better pain killing effects, effective immunomodulation, control of inflammation, and (neo) angiogenesis, ultimately contributing to functionally restored body movement patterns. MDPI 2022-11-15 /pmc/articles/PMC9687216/ /pubmed/36428501 http://dx.doi.org/10.3390/biomedicines10112933 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Everts, Peter A.
Mazzola, Timothy
Mautner, Kenneth
Randelli, Pietro S.
Podesta, Luga
Modifying Orthobiological PRP Therapies Are Imperative for the Advancement of Treatment Outcomes in Musculoskeletal Pathologies
title Modifying Orthobiological PRP Therapies Are Imperative for the Advancement of Treatment Outcomes in Musculoskeletal Pathologies
title_full Modifying Orthobiological PRP Therapies Are Imperative for the Advancement of Treatment Outcomes in Musculoskeletal Pathologies
title_fullStr Modifying Orthobiological PRP Therapies Are Imperative for the Advancement of Treatment Outcomes in Musculoskeletal Pathologies
title_full_unstemmed Modifying Orthobiological PRP Therapies Are Imperative for the Advancement of Treatment Outcomes in Musculoskeletal Pathologies
title_short Modifying Orthobiological PRP Therapies Are Imperative for the Advancement of Treatment Outcomes in Musculoskeletal Pathologies
title_sort modifying orthobiological prp therapies are imperative for the advancement of treatment outcomes in musculoskeletal pathologies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9687216/
https://www.ncbi.nlm.nih.gov/pubmed/36428501
http://dx.doi.org/10.3390/biomedicines10112933
work_keys_str_mv AT evertspetera modifyingorthobiologicalprptherapiesareimperativefortheadvancementoftreatmentoutcomesinmusculoskeletalpathologies
AT mazzolatimothy modifyingorthobiologicalprptherapiesareimperativefortheadvancementoftreatmentoutcomesinmusculoskeletalpathologies
AT mautnerkenneth modifyingorthobiologicalprptherapiesareimperativefortheadvancementoftreatmentoutcomesinmusculoskeletalpathologies
AT randellipietros modifyingorthobiologicalprptherapiesareimperativefortheadvancementoftreatmentoutcomesinmusculoskeletalpathologies
AT podestaluga modifyingorthobiologicalprptherapiesareimperativefortheadvancementoftreatmentoutcomesinmusculoskeletalpathologies